Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions
2024

Advances in DLL3-targeted therapies for small cell lung cancer

publication Evidence: moderate

Author Information

Author(s): Ding Jianhua, Yeong Chaihong

Primary Institution: Taylor’s University, Subang Jaya, Selangor, Malaysia

Hypothesis

The review explores the evolving landscape of DLL3-targeted therapies in small cell lung cancer (SCLC), examining their mechanistic basis, preclinical promise, and clinical development.

Conclusion

DLL3-targeted therapies hold the potential to revolutionize treatment paradigms for small cell lung cancer.

Supporting Evidence

  • Recent advances in understanding SCLC biology have identified DLL3 as a promising target for novel therapies.
  • Emerging bispecific T-cell engagers represent a new frontier in DLL3-directed immunotherapy.
  • Current research efforts are focused on harnessing the Notch signaling pathway in SCLC through DLL3-targeted therapies.

Takeaway

This study looks at new treatments for a type of lung cancer that targets a specific protein called DLL3, which could help doctors treat patients better.

Methodology

The review discusses various therapeutic modalities, including antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapies.

Limitations

The review highlights challenges in translating DLL3-targeted therapies into clinical practice, including setbacks faced by early therapies.

Digital Object Identifier (DOI)

10.3389/fonc.2024.1504139

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication